Measuring the Efficacy and Value of Urothelial Cancer Urinary Biomarkers
Authors: Phillip H. Abbosh, Elizabeth R. Plimack
Journal: Annals of Internal Medicine (2015)

Editorials15 December 2015Measuring the Efficacy and Value of Urothelial Cancer Urinary BiomarkersPhillip H. Abbosh, MD, PhD and Elizabeth R. Plimack, MD, MSPhillip H. Abbosh, MD, PhDFrom Fox Chase Cancer Center, Philadelphia, Pennsylvania. and Elizabeth R. Plimack, MD, MSFrom Fox Chase Cancer Center, Philadelphia, Pennsylvania.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M15-2445 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The initial diagnosis of bladder cancer most often occurs after an episode of gross or microscopic hematuria. The recommended work-up for gross hematuria includes cystoscopy, cytologic evaluation, and imaging (1). The risk for tumors during a hematuria work-up ranges from 2% to 20% and depends on whether the patient had gross or microscopic hematuria, as well as tobacco exposure, sex, exposure to radiation or occupational carcinogens, and history of urologic tumors. Up to 30% of patients with newly diagnosed bladder cancer will have muscle-invasive disease at the initial diagnosis, suggesting an opportunity for screening tests to identify disease in earlier ...References1. Yun EJ, Meng MV, Carroll PR. Evaluation of the patient with hematuria. Med Clin North Am. 2004;88:329-43. [PMID: 15049581] CrossrefMedlineGoogle Scholar2. Murakami S, Igarashi T, Hara S, Shimazaki J. Strategies for asymptomatic microscopic hematuria: a prospective study of 1,034 patients. J Urol. 1990;144:99-101. [PMID: 2193173] CrossrefMedlineGoogle Scholar3. Chou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, et al. Urinary biomarkers for diagnosis of bladder cancer. A systematic review and meta-analysis. Ann Intern Med. 2015;163:922-31. doi:10.7326/M15-0997 LinkGoogle Scholar4. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000;2:116-23. [PMID: 11229514] CrossrefMedlineGoogle Scholar5. Fradet Y, Lockhard C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. Can J Urol. 1997;4:400-405. [PMID: 12735818] MedlineGoogle Scholar6. O'Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L, et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. 2012;188:741-7. [PMID: 22818138] doi:10.1016/j.juro.2012.05.003 CrossrefMedlineGoogle Scholar7. Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer. 1999;87:118-28. [PMID: 10385442] CrossrefMedlineGoogle Scholar8. Malik SN, Murphy WM. Monitoring patients for bladder neoplasms: what can be expected of urinary cytology consultations in clinical practice. Urology. 1999;54:62-6. [PMID: 10414728] CrossrefMedlineGoogle Scholar9. Wiener HG, Vooijs GP, van't Hof-Grootenboer B. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol. 1993;37:163-9. [PMID: 8465635] MedlineGoogle Scholar10. Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int. 2011;108:1119-23. [PMID: 21426474] doi:10.1111/j.1464-410X.2010.10026.x CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Phillip H. Abbosh, MD, PhD; Elizabeth R. Plimack, MD, MSAffiliations: From Fox Chase Cancer Center, Philadelphia, Pennsylvania.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-2445.Corresponding Author: Elizabeth R. Plimack, MD, MS, Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.Current Author Addresses: Dr. Abbosh: Department of Surgical Oncology, Division of Urologic Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.Dr. Plimack: Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.This article was published online first at www.annals.org on 27 October 2015. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoUrinary Biomarkers for Diagnosis of Bladder Cancer Roger Chou , John L. Gore , David Buckley , Rongwei Fu , Katie Gustafson , Jessica C. Griffin , Sara Grusing , and Shelley Selph Metrics Cited byThe identification of new biomarkers for bladder cancer: A study based on TCGA and GEO datasets 15 December 2015Volume 163, Issue 12Page: 954-955KeywordsBladder cancerCellsCystoscopyFluorescence in situ hybridizationPositive predictive valueProteinsSpecificitySystematic reviewsUrinary biomarkersUrine ePublished: 27 October 2015 Issue Published: 15 December 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...